Novel antipsychotics in bipolar and schizoaffective mania.

Autor: Mensink GJ; Department of Psychotic Disorders, Mental Health Centre Drenthe, Assen, The Netherlands., Slooff CJ
Jazyk: angličtina
Zdroj: Acta psychiatrica Scandinavica [Acta Psychiatr Scand] 2004 Jun; Vol. 109 (6), pp. 405-19.
DOI: 10.1111/j.1600-0047.2004.00295.x
Abstrakt: Objective: Novel antipsychotics are increasingly used in the treatment of bipolar and schizoaffective mania. This paper presents an overview of the controlled studies in this field.
Method: Using cross-references, a computerized search was performed on MEDLINE and EMBASE psychiatry covering the period 1990-2002.
Results: Olanzapine and risperidone, added to mood stabilizers, and olanzapine as monotherapy enjoy the most evidential support in terms of efficacy and side-effect profile for their use in acute bipolar mania. The use of modern antipsychotics in bipolar prophylaxis and in both the short- and long-term treatment of schizomania has not been widely studied yet.
Conclusion: More controlled trials are still needed comparing modern antipsychotics as monotherapy and adjunctive to mood stabilizers with conventional antipsychotics, lithium, anticonvulsants and with each other in short-term and, especially, maintenance treatment of (schizo)mania. Partly based on controlled studies, olanzapine, risperidone and other modern antipsychotics could become preferable for these indications.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje